[{"id":"1cd30a79-c1e8-4431-840c-119876b931fc","acronym":"LU21-16","url":"https://clinicaltrials.gov/study/NCT05277701","created_at":"2022-03-14T14:54:14.146Z","updated_at":"2024-07-02T16:36:15.482Z","phase":"Phase 2","brief_title":"Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations","source_id_and_acronym":"NCT05277701 - LU21-16","lead_sponsor":"Yonsei University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747S • EGFR E709A","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747S • EGFR E709A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lazcluze (lazertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-03-14"}]